The presence and influence of mild depressive symptoms on post-operative pain perception following primary total knee arthroplasty.

PURPOSE: To evaluate the influence of mild depression on pain perception after total knee arthroplasty (TKA). METHODS: Hamilton depression (HDRS) and numeric rating (NRS) scales were used to evaluate depression severity and pain perception at various intervals surrounding TKA. The Hospital for Special Surgery (HSS) knee and pain scores (NRS) in patients with signs of mild depression (HDRS < 20 points) were compared to a control group of patients with no signs of depression (HDRS < 8 points). RESULTS: Prior to surgery, there were no statistical differences in pain perception (NRS) or individual components of HSS knee score including range of motion, pain, and function between patients with mild depression compared to controls. However, following surgery, patients with signs of mild depression were more likely to report more pain (p < 0.001) and have lower HSS scores even at 1 year post-operatively (p < 0.001). CONCLUSIONS: A significant number of patients in this series undergoing routine primary TKA had signs of subclinical depression. These patients are more likely to report increased pain even at 1 year following surgery compared to patients without signs of depression preoperatively. Psychometric evaluation prior to surgery can help identify the at-risk patient and allow for proper management of patient expectations, thus improving clinical results and patients' satisfaction after TKA. LEVEL OF EVIDENCE: Prospective comparative study, II.

Multimodal Analgesia in Total Knee Arthroplasty: A Randomized, Double-Blind, Controlled Trial on Additional Efficacy of Periarticular Anesthesia.

Pain management is a main determinant of functional recovery after total knee arthroplasty (TKA). We performed a randomized, controlled, double blind study to evaluate additive efficacy of periarticular anesthesia in patients undergoing TKA in reducing post-operative pain, operated limb edema and improving post-operative mobility. Patients were randomly assigned to study or control group; all subjects received the same analgesic protocol; before wound closure, the study group received also a periarticular anesthesia (ropivacaine 1% 20 mL). The results show no statistical differences in any of the variable evaluated. Our data suggest that additive periarticular anesthetic protocol with ropivacaine 1% 20 mL is not superior to oral and intravenous analgesia alone in patients undergoing TKA, regarding post-operative pain control, operated limb edema reduction and post-operative mobility improvement.

Mobile smartphone applications for body position measurement in rehabilitation: a review of goniometric tools.

OBJECTIVE: To provide a systematic review of apps for smartphones validated for body position measurement relevant to physical medicine and rehabilitation. TYPE: Systematic search and review. LITERATURE SURVEY: A literature search was conducted on relevant articles indexed by PubMed before April 15, 2014. We selected only research papers published in English. Papers dealing with apps not relevant to physical medicine and rehabilitation or unavailable on the market were excluded. METHODOLOGY: Two independent reviewers screened the articles (full text).We analyzed the following information for all apps: target population, object of the measure, body segment evaluated, modality of use, operating platform system, and validation results. SYNTHESIS: The literature search produced 27 papers, 17 of which met the inclusion criteria for our review. The included papers featured 12 apps validated for angle measurement: 7 were validated exclusively for upper and lower limb joint angles, 4 for spine measurements, ie, cervical or lumbar range of motion and curvature, Cobb angle on radiographs, and the scoliotic distortions of the torso, and 1 for both upper limb and spine measurement. The 12 apps used the inbuilt smartphone magnetometer, accelerometer, or camera to produce angle measurements. Most of the studies assessed the smartphone-apps' reliability (calculating the intraclass correlation coefficients) and validity (showing the limits of agreement). CONCLUSION: This review highlights the validated goniometer apps that physiatrists and other health care practitioners can use with confidence in research and clinical practice. We found 12 apps corresponding to these criteria, but there is a need for validation studies on available or new apps focused on goniometric measurement in dynamic conditions, eg, during gait or when performing therapeutic exercises.

Acute compartment syndrome of the arm after minor trauma in a patient with optimal range of oral anticoagulant therapy: a case report.

Compartment syndrome of the arm is a rare event that can be subsequent to trauma or other pathological and physical conditions. At the arm the thin and elastic fascia may allow accumulation of blood more than in other districts, especially in patients undergoing anticoagulant therapy. We describe a rare case of an acute compartment syndrome of the arm after minor trauma with partial biceps brachii rupture in a patient with warfarin therapy and optimal value of INR. Prompt diagnosis and surgical decompression helped to avoid the occurrence of complications with a satisfying recovery of arm function.

Incontinentia pigmenti: a rare pathology with complex rehabilitative aspects.

PURPOSE: Incontinentia pigmenti (IP), or Bloch-Sulzberger syndrome, is a rare X-linked dominant genetic disorder with multisystem involvement. To our knowledge, there are no previous reports about rehabilitation in IP adult with intact cognitive development. We report a 20-year-old lady with IP managed and followed into adulthood. METHOD: Patient management and rehabilitation programs from birth to the last follow-up. RESULTS: There was normal cognitive development despite magnetic resonance imaging (MRI) evidence of white matter, corpus callosum and brainstem hypoplasia. Extensor spasticity was present on both lower limbs for which she underwent rehabilitation from the age of one. Botulinum toxin injections were performed and when she was 15 years old she underwent functional surgery. CONCLUSION: The absence of mental retardation in our patient enabled us to carry out an active rehabilitation program and provide her with maximum independence in locomotion and in activities of daily living. IMPLICATIONS FOR REHABILIATION: Incontinentia pigmenti (Bloch-Sulzberger syndrome). Incontinentia pigmenti is a rare X-linked dominant genetic disorder with multisystemic involvement. Skin lesions, neurological impairments, motormental retardation, skeletal congenital defects and ophthalmologic involvement are IP most frequent manifestations. Due to the complex multisystem involvement resulting in severe long-term disability, patients with IP require a multidisciplinary team approach for rehabilitation. In IP patients, rehabilitation interventions should always take into consideration the individual phenotype expression, child's physical development and personal needs.

Development and validation of the Italian version of the Spinal Cord Independence Measure III.

PURPOSE: To provide a translation and cultural adaptation of the Spinal Cord Independence Measure version III scale for Italy (i-SCIM3) and to validate this version of the scale. METHOD: i-SCIM3 was developed involving a forward-backward translation and administered to patients with spinal cord lesions (SCL) admitted to two centers. Two raters for each center evaluated patients at admission and discharge. Psychometric testing included reliability by internal consistency (Cronbach's alpha) and test-retest reliability. The validity of i-SCIM3 was assessed by comparing it with the Italian version of Functional Independence Measure (FIM). RESULTS: One hundred three adult patients with SCL (84 males) with a mean age of 50.33+/-15.35 years were recruited. Seventy-four patients were paraplegic and 29 patients were tetraplegic. The median time elapsed between the two evaluations was 77.5 days (interquartile range, 53-144 days). Internal consistency, inter-rater reliability, and test-retest reliability were satisfactory overall, showing values higher than 0.90. The validity of i-SCIM3 was confirmed by the close correlation with FIM results both at admission and discharge (r=0.91, p<0.01). The sensitivity to change of i-SCIM3 was similar to that of FIM. CONCLUSION: i-SCIM3 was found to be a consistent, reliable, and valid scale for use in the clinical setting. It is the first validated scale in Italian for patients with SCL.

Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance.

BACKGROUND: Renal function is a powerful prognostic variable in patients with heart failure (HF). Hospitalisations for acute HF (AHF) may be associated with further worsening of renal function (WRF). METHODS AND RESULTS: We analysed the clinical significance of WRF in 318 consecutive patients admitted at our institute for AHF. WRF was defined as the occurrence, at any time during the hospitalisation, of both a > or =25% and a > or =0.3 mg/dL increase in serum creatinine (s-Cr) from admission (WRF-Abs-%). RESULTS: Patients were followed for 480+/-363 days. Fifty-three patients (17%) died and 132 (41%) were rehospitalised for HF. WRF-Abs-% occurred in 107 (34%) patients. At multivariable survival analysis, WRF-Abs-% was an independent predictor of death or HF rehospitalisation (adjusted HR, 1.47; 95%CI, 1.13-1.81; p=0.024). The independent predictors of WRF-Abs-%, evaluated using multivariable logistic regression, were history of chronic kidney disease (p=0.002), LV ejection fraction (p=0.012), furosemide daily dose (p=0.03) and NYHA class (p=0.05) on admission. CONCLUSION: WRF is a frequent finding in patients hospitalised for AHF and is associated with a poor prognosis. Severity of HF and daily furosemide dose are the most important predictors of the occurrence of WRF.

The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T.

AIMS: Brain natriuretic peptide (BNP), NT-proBNP and troponins are useful for the assessment of patients with heart failure. Few data exist about their serial changes and their prognostic value in patients with acute heart failure (AHF). METHODS AND RESULTS: NT-proBNP and troponin-T plasma levels were measured at baseline, after 6, 12, 24, 48 h and at discharge in 116 consecutive patients with AHF and no evidence of acute coronary syndrome. NT-proBNP levels were 4421 pg/mL at baseline, declined after 24 h and reached their nadir at 48 h (2703 pg/mL). Troponin-T was detectable in 48% of patients. During a median follow-up of 184 days, 52 patients died or had a non-fatal cardiovascular hospitalisation. At a multivariable analysis including clinical and echo-Doppler variables, NT-proBNP plasma levels at discharge, detectable troponin-T plasma levels, and NYHA class at discharge were the only independent prognostic factors. CONCLUSION: In patients with AHF, NT-proBNP levels decline 24 h after the initiation of intravenous therapy and troponin-T is detectable in 48% of cases. NT-proBNP levels at discharge, detectable troponin-T levels, NYHA class and serum sodium have independent prognostic value.

Clinical trials update from the World Congress of Cardiology 2006.

This article provides information on trials presented at the World Congress of Cardiology 2006 (WCC-2006). This was a joint meeting of the European Society of Cardiology and the World Heart Federation. Heart failure trials dealing with understudied patient populations (e.g., the elderly), trials of new treatments (i.e., immune modulation therapy) and new intervention strategies (i.e., the Cardiac Insufficiency Bisoprol-III study) or patient monitoring (the Home or Hospital Heart Failure study) were presented at this meeting. Among the studies about coronary artery disease treatment, WCC-2006 saw the presentation of the landmark meta-analyses regarding the incidence of late events in patients receiving drug-eluting stents. The main results of these meta-analyses, and the associated debate, are summarised in this article. Finally, the results of other trials of percutaneous patent foramen ovale closure and atrial fibrillation treatment in elderly patients are summarised.

Beta-blocker therapy of heart failure: an update.

The beneficial effects of beta-blocker therapy in patients with heart failure have been consistently shown by multi-center randomised trials. These agents are effective and also relatively well tolerated in the elderly and in patients with diabetes and advanced heart failure--traditionally considered as relative contraindications to their administration. However, the use of beta-blockers in clinical practice remains low. The difficulties in their initiation and up-titration may be overcome by patient and physician education, as well as by their initiation during hospitalisation and/or the involvement of non-physician providers (i.e., a nurse facilitator). Forthcoming advances in the pharmacokinetic and pharmacodynamic characteristics of some beta-blockers, and testing of novel methods for patient and drug selection may be based on genetic testing, and may allow further improvement of beta-blocker therapy in the next future.

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.

Clinical trials have consistently shown the benefits of beta-blocker treatment in patients with chronic heart failure (HF). As a result, bisoprolol, carvedilol, and metoprolol succinate are now indicated for the treatment of all patients with chronic HF who do not have major contraindications. Bisoprolol is the first beta-blocker shown to improve survival in an outcome trial. In the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), all-cause mortality and sudden death were reduced in patients treated with bisoprolol compared with those on placebo (11.8% vs 17.3%; p < 0.0001 and 3.6% vs 6.3%, p < 0.002; respectively) regardless of age, NYHA functional class, and co-morbidities. Further studies have shown both the efficacy of bisoprolol on secondary endpoints and patients subgroups as well its high cost effectiveness. More recently, CIBIS-III has shown similar efficacy and safety of the initiation of HF treatment with either bisoprolol or enalapril, with a tendency to a survival advantage with bisoprolol. Nowadays, the role of bisoprolol, as well as that of carvedilol and metoprolol succinate, in HF treatment is firmly established and research is mainly focused on implementation of treatment and better dosing. This article will summarize evidence for the efficacy of bisoprolol in the treatment of HF.